PHARMACEUTICAL 2024

Lifecore Biomedical INC DE
Rank 195 of 309



PHARMACEUTICAL 2024

LANDEC

Lifecore Biomedical INC DE
Rank 195 of 309

The relative strengths and weaknesses of Lifecore Biomedical INC DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lifecore Biomedical INC DE compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 27% points.The greatest weakness of Lifecore Biomedical INC DE is the variable Stockholders Equity, reducing the Economic Capital Ratio by 90% points.

The company's Economic Capital Ratio, given in the ranking table, is 146%, being 67% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	93,875
Cost of Goods Sold	75,284
Intangible Assets	18,081
Liabilities, Current	39,289
Liabilities, Non-Current	87,370
Other Assets	7,199
Other Compr. Net Income	-34,741
Other Expenses	2,384
Other Liabilities	91,798
Other Net Income	-24,900
Other Revenues	103,618
Property and Equipment	134,390
Research and Development	8,736
Selling, General and Administrative Expense	38,969

Output Variable	Value in 1000 USD
Assets	253,545
Liabilities	218,457
Expenses	125,373
Revenues	103,618
Stockholders Equity	35,088
Net Income	-46,655
Comprehensive Net Income	-64,026
BaseVar	380,317
ECR before LimitedLiability	5.3%
Economic Capital Ratio	146%